Non-combustible nicotine products—vapes, heated tobacco, and especially nicotine pouches—are widely understood to be far less harmful than smoking, a point I and many others have covered repeatedly, and one that no longer sits at the frontier of scientific debate. At the same time, the political panic that once drove restrictive policy has subsided, with youth vaping falling sharply from its peak.

The most recent data show that around 5.2 percent of youth report e-cigarette use in the past 30 days, down dramatically from prior highs, and importantly only a subset of that group are frequent users, those using on 20 or more days in a month, the category most closely associated with dependence. 

Nicotine pouch use among youth is lower still, at roughly 1.7 percent. Much of what remains appears to be occasional or experimental rather than habitual. These are not crisis numbers, and they matter because they directly undercut the primary justification for continued regulatory paralysis.

One might expect regulators to respond accordingly, adjusting policy to reflect both the risk gradient and the changed behavioral landscape, but that has not happened. Instead, the system has stalled, quietly but decisively, with approvals for new products slowing to a near standstill. 

At the center of that paralysis sits Marty Makary, head of the U.S. Food and Drug Administration, and increasingly the explanation for inaction appears not to lie in scientific uncertainty or bureaucratic complexity, but in his simple unwillingness to move.

According to several informed sources, there is now a clear split within the administration, with parts of the FDA Center for Tobacco Products and broader White House advisers recognizing that harm reduction is both scientifically grounded and politically manageable. 

Notably, Robert F. Kennedy, Jr. is described as supportive of this shift, particularly in relation to nicotine pouches. Kennedy is reported to use nicotine pouches himself and to view them as a practical, low-risk alternative for adults, which in policy terms should make them the least controversial category, given that they involve no combustion, no smoke, and no tobacco leaf. In almost any rational regulatory framework, these products would be the easiest to authorize.

Yet they are not being authorized, and the reason, according to sources, is that Makary has become the effective blockade, with approvals held up despite falling youth use and despite data generated within his own government pointing in a consistent direction. This is less a disagreement over interpretation than a refusal to act on available evidence, and the explanation offered by those familiar with the situation is not primarily scientific, but personal, tied to concerns about legacy.

Makary is said to be focused on avoiding reputational risk, particularly given uncertainty about the length of his tenure, with the concern that authorizing new nicotine products could, if later criticized, define his time at the FDA. Blocking approvals, by contrast, carries no immediate cost, and in that calculation inaction becomes the safer choice for the individual making the decision, even if it is the costlier choice for public health.